ASH 2020 RWE

Real-world evidence research presented at The American Society of Hematology (ASH) Annual Meeting

Last updated: June 10, 2021

Real-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia After Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL)

Ian J. Hooley et al.

Ian J. Hooley et al.

Patients with CLL receiving anti-CD20 monoclonal antibody (mAb) therapy are at risk of low levels of gamma globulins in the blood, also known as hypogammaglobulinemia. This may lead to an impaired immune system and an increased risk of infection. Real-world immunoglobulin G (IgG) testing rates haven’t been extensively studied and thus it’s unclear the extent to which gamma globulin levels change before and after mAb therapy.

Using an EHR-derived real-world dataset, researchers investigated IgG testing rates as well as the factors that increased the likelihood of new onset hypogammaglobulinemia following anti-CD20 therapy.

Why this matters

In settings where treatments are used, long-term, clinical trials may offer a truncated perspective of the implications over time of specific aspects of a therapeutic profile.

Real world data provides a unique tool to address this gap. In this case, an EHR-derived database was used to gain insight on the management and impact of hypogammaglobulinemia associated with anti-CD20 agents in patients with CLL. Reaching a deeper understanding of this under-studied adverse event is growing in importance as more potent B-cell depleting therapies enter the market.

View the full abstract on the ASH website
ASH-Hooley
Chart of patient flow showing 479 patients with an IgG test during detection window using RWD
Hear Ian J. Hooley discuss real-world immunoglobulin G testing frequency in patients with CLL.

Patients with CLL receiving anti-CD20 monoclonal antibody (mAb) therapy are at risk of low levels of gamma globulins in the blood, also known as hypogammaglobulinemia. This may lead to an impaired immune system and an increased risk of infection. Real-world immunoglobulin G (IgG) testing rates haven’t been extensively studied and thus it’s unclear the extent to which gamma globulin levels change before and after mAb therapy.

Using an EHR-derived real-world dataset, researchers investigated IgG testing rates as well as the factors that increased the likelihood of new onset hypogammaglobulinemia following anti-CD20 therapy.

Why this matters

In settings where treatments are used, long-term, clinical trials may offer a truncated perspective of the implications over time of specific aspects of a therapeutic profile.

Real world data provides a unique tool to address this gap. In this case, an EHR-derived database was used to gain insight on the management and impact of hypogammaglobulinemia associated with anti-CD20 agents in patients with CLL. Reaching a deeper understanding of this under-studied adverse event is growing in importance as more potent B-cell depleting therapies enter the market.

View the full abstract on the ASH website

View more arrow_viewmore_02

Real-World Outcomes of Patients with Diffuse Large B-Cell Lymphoma Receiving Second Line Therapy in the United States

Ahmed Sawas et al.

Ahmed Sawas et al.

Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will relapse after front-line therapy and prognosis after relapse remains poor. New therapies are emerging for the treatment of patients with relapsed DLBCL but more needs to be understood about overall survival of these patients in the real world. Researchers interrogated an EHR-derived database to investigate which factors specifically affect prognosis and which therapeutic approaches are predominant in the second-line setting.

Why this matters

It is known that once first-line treatment fails, patients with DLBCL face suboptimal treatment options and a dismal prognosis. Overall patient management in second-line DLBCL is complex as practitioners balance the suitability of autologous transplant and/or systemic therapies for each individual patient.

Having a richer knowledge base of this patient population to tailor the clinical development, and ultimately the use of novel therapeutic options will be key.

View the full abstract on the ASH website
Sawas figure
Unadjusted real-world overall survival from second-line initiation.
Listen to Ahmed Sawas, MD and Constance Lau, MPH discuss the real-world outcomes of patients with DLBCL receiving 2L therapy.

Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will relapse after front-line therapy and prognosis after relapse remains poor. New therapies are emerging for the treatment of patients with relapsed DLBCL but more needs to be understood about overall survival of these patients in the real world. Researchers interrogated an EHR-derived database to investigate which factors specifically affect prognosis and which therapeutic approaches are predominant in the second-line setting.

Why this matters

It is known that once first-line treatment fails, patients with DLBCL face suboptimal treatment options and a dismal prognosis. Overall patient management in second-line DLBCL is complex as practitioners balance the suitability of autologous transplant and/or systemic therapies for each individual patient.

Having a richer knowledge base of this patient population to tailor the clinical development, and ultimately the use of novel therapeutic options will be key.

View the full abstract on the ASH website

View more arrow_viewmore_02